Side-by-side comparison of AI visibility scores, market position, and capabilities
Fremont CA solar microinverters (NASDAQ: ENPH) at $1.33B 2024 revenue (-42% correction); IQ microinverters + IQ Battery home energy system, 53.2% gross margin, residential solar demand recovery play competing with SolarEdge.
Enphase Energy, Inc. is a Fremont, California-based energy technology company — publicly traded on NASDAQ (NASDAQ: ENPH) as an S&P 500 Information Technology component — designing, manufacturing, and selling the IQ microinverter system for residential and commercial solar photovoltaic installations, the IQ Battery home energy storage system, and the IQ EV charger through approximately 3,700 employees worldwide. Enphase pioneered the microinverter architecture — where each individual solar panel has its own dedicated DC-to-AC inverter, compared to central string inverters that connect multiple panels in series — creating a system where one shaded or underperforming panel does not reduce the output of the entire array. In Q4 2024, Enphase reported revenue of $382.7 million (53.2% non-GAAP gross margin), shipping approximately 2.01 million microinverters (878 MW DC) and 152.4 MWh of IQ Batteries, with free cash flow of $159.2 million. Full year 2024 revenue was $1.33 billion, down 42% from 2023's peak — reflecting significant headwinds from elevated interest rates suppressing residential solar financing demand, an installer channel inventory correction as distributors worked down excess microinverter stock accumulated during the 2022-2023 supply chain restock, and European market softness. CEO Badri Kothandaraman has managed the demand cycle correction while maintaining Enphase's industry-leading gross margins and strong balance sheet ($1.72 billion in cash and marketable securities at year-end 2024).
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.